{"title":"Lokivetmab -治疗和控制犬特应性皮炎的新选择综述","authors":"Mariana B. Mascarenhas, Cristiane Bazaga Botelho","doi":"10.46958/rcv.2019.xxiv.n.141.p.34-38","DOIUrl":null,"url":null,"abstract":"Monoclonal antibodies have been studied in human medicine for a while. They target specific receptors and cytokines, and are highly specific and effective in blocking their target molecule. Lokivetmab is a monoclonal caninised anti-IL-31 antibody that was recently approved for the treatment of atopic dermatitis in dogs. Currently, no other therapeutic monoclonal antibody is used in veterinary medicine. The goal of this review of literature is to updte clinicians on this new biological option for treatment of canine atopic dermatitis.","PeriodicalId":10255,"journal":{"name":"Clínica Veterinária","volume":"126 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Lokivetmab – a new option for the treatment and control of canine atopic dermatitis – review\",\"authors\":\"Mariana B. Mascarenhas, Cristiane Bazaga Botelho\",\"doi\":\"10.46958/rcv.2019.xxiv.n.141.p.34-38\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Monoclonal antibodies have been studied in human medicine for a while. They target specific receptors and cytokines, and are highly specific and effective in blocking their target molecule. Lokivetmab is a monoclonal caninised anti-IL-31 antibody that was recently approved for the treatment of atopic dermatitis in dogs. Currently, no other therapeutic monoclonal antibody is used in veterinary medicine. The goal of this review of literature is to updte clinicians on this new biological option for treatment of canine atopic dermatitis.\",\"PeriodicalId\":10255,\"journal\":{\"name\":\"Clínica Veterinária\",\"volume\":\"126 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clínica Veterinária\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.46958/rcv.2019.xxiv.n.141.p.34-38\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clínica Veterinária","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.46958/rcv.2019.xxiv.n.141.p.34-38","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Lokivetmab – a new option for the treatment and control of canine atopic dermatitis – review
Monoclonal antibodies have been studied in human medicine for a while. They target specific receptors and cytokines, and are highly specific and effective in blocking their target molecule. Lokivetmab is a monoclonal caninised anti-IL-31 antibody that was recently approved for the treatment of atopic dermatitis in dogs. Currently, no other therapeutic monoclonal antibody is used in veterinary medicine. The goal of this review of literature is to updte clinicians on this new biological option for treatment of canine atopic dermatitis.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
